Biomarkers of Acute Kidney Injury

Biomarkers: In Medicine, Drug Discovery, and Environmental Health

Volumn , Issue , 2010, Pages 237-279

  Dieterle, Frank ^a   Sistare, Frank D ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Acute kidney injury; Expression markers; Functional biomarkers; Kidney safety biomarkers; Leakage markers

Indexed keywords

EID: 84885979179     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470918562.ch10     Document Type: Chapter

References (244)

1. Wu, I. N. S. and Parikh, C. R. Screening Dor Kidney Diseases: Older Measures versus Novel Biomarkers. Clin. J. Am. Soc. Nephrol. Nov 2008;3(6):1895-1901.
2. Meguid, E. L., Nahas, A., and Bello, A. K. Chronic Kidney Disease: The Global Challenge. Lancet. 2005;365(9456):331-340.
3. Hou, S. H., Bushinsky, D. A., Wish, J. B., Cohen, J. J., and Harrington, J. T. Hospital-Acquired Renal Insufficiency: A Prospective Study. Am. J. Med. 1983;74(2):243-248.
4. Shusterman, N., Strom, B. L., Murray, T. G., Morrison, G., West, S. L., and Mais-lin, G. Risk Factors and Outcome of Hospital-Acquired Acute Renal Failure. Clinical Epidemiologic Study. Am. J. Med. 1987;83(1):65-71.
5. Liangos, O., Wald, R., O'Bell, J. W., Price, L., Pereira, B. J., and Jaber, B. L. Epidemiology and Outcomes of Acute Renal Failure in Hospitalized Patients: A National Survey. Clin. J. Am. Soc. Nephrol. Jan 2006;1(1):43-51.
6. Nash, K., Hafeez, A., and Hou, S. Hospital-Acquired Renal Insufficiency. Am. J. Kidney Dis. 2002;39(5):930-936.
7. Chertow, G. M., Levy, E. M., Hammermeister, K. E., Grover, F, and Daley, J. Independent Association between Acute Renal Failure and Mortality Following Cardiac Surgery. Am. J. Med. 1998;104(4):343-348.
8. De Mendonca, A., Vincent, J. L., Suter, P. M., Moreno, R., Dearden, N. M., Antonelli, M., Takala, J., Sprung, C, and Cantraine, F. Acute Renal Failure in the ICU: Risk Factors and Outcome Evaluated by the SOFA Score. Intensive Care Med. 2000;26(7):915-921.
9. Trof, R. J., Di Maggio, F, Leemreis, J., and Groeneveld, A. B. Biomarkers of Acute Renal Injury and Renal Failure. Shock. 2006;26(3):245-253.
10. Mehta, R. L., Pascual, M. T., Soroko, S., Savage, B. R., Himmelfarb, J., and Ikizler, T. A., et al. Spectrum of Acute Renal Failure in the Intensive Care Unit: The PICARD Experience. Kidney Int. 2004;66(4):1613-1621.
11. Radhakrishnan, J. and Kiryluk, K. Acute Renal Failure Outcomes in Children and Adults. Kidney Int. 2006;69(1):17-19.
12. Ympa, Y. P., Sakr, Y., Reinhart, K., and Vincent, J. L. Has Mortality From Acute Renal Failure Decreased? A Systematic Review of the Literature. Am. J. Med. 2005;118(8):827-832.
13. Bellomo, R. The Epidemiology of Acute Renal Failure: 1975 versus 2005. Curr. Opin. Crit. Care. Dec 2006;12(6):557-560.
14. Levy, E. M., Viscoli, C. M., and Horwitz, R. I. The Effect of Acute Renal Failure on Mortality. A Cohort Analysis. JAMA. 1996;275(19):1489-1494.
15. Parikh, C. R., McSweeney, P., and Schrier, R. W. Acute Renal Failure Independently Predicts Mortality After Myeloablative Allogeneic Hematopoietic Cell Transplant. Kidney Int. 200;67(5):1999-2005.
16. Waikar, S. S., Curhan, G. C, Wald, R., McCarthy, E. P., and Chertow, G. M. Declining Mortality in Patients with Acute Renal Failure, 1988 to 2002. J. Am. Soc. Nephrol. Apr 2006;17(4):1143-1150.
17. Mehta, R. L., Kellum, J. A., Shah, S. V, Molitoris, B. A., Ronco, C, Warnock, D. G., and Levin, A. et al. Acute Kidney Injury Network: Report of an Initiative to Improve Outcomes in Acute Kidney Injury. Crit. Care. 2007;11(2):R31.
18. Thadhani, R., Pascual, M., and Bonventre, J. V. Acute Renal Failure. N. Engl. J. Med. 1996;334(22):1448-1160.
19. Vaidya, V. S., Ferguson, M. A., and Bonventre, J. V. Biomarkers of Acute Kidney Injury. Annu. Rev. Pharmacol Toxicol. 2008;48:463-93.
20. Zhang, L., Wang, M., and Wang, H. Acute Renal Failure in Chronic Kidney Disease-Clinical and Pathological Analysis of 104 Cases. Clin. Nephrol. May 2005;63(5):346-350.
21. Zuk, A., Bonventre, J. V, Brown, D., and Matlin, K. S. Polarity, Integrin, and Extracellular Matrix Dynamics in the Postischemic Rat Kidney. Am. J. Physiol. 1998;275:C711-31.
22. Zuk, A., Bonventre, J. V., and Matlin, K. S. Expression of Fibronectin Splice Variants in the Postischemic Rat Kidney. Am. J. Physiol. Renal Physiol. 2001;280(6):F1037-1053.
23. Bonventre, J. V. and Zuk, A. Ischemic Acute Renal Failure: An Inflammatory Disease? Kidney Int. 2004;66(2):480-485.
24. Bonventre, J. V. Dedifferentiation and Proliferation of Surviving Epithelial Cells in Acute Renal Failure. J. Am. Soc. Nephrol. 2003;14 Suppl LS55-61.
25. Vaidya, V. S., Shankar, K., Lock, E. A., Bucci, T. J., and Mehendale, H. M. Role of Tissue Repair in Survival From S-( 1,2-Dichlorovinyl)-L-Cysteine-Induced Acute Renal Tubular Necrosis in the Mouse. Toxicol. Sci. 2003;74(1):215-227.
26. Lameire, N. and Hoste, E. Reflections on the Definition, Classification, and Diagnostic Evaluation of Acute Renal Failure. Curr. Opin. Crit. Care. 2004;10(6):468-475.
27. Bellomo, R., Ronco, C, Kellum, J. A., Mehta, R. L., and Palevsky, P. Acute Dialysis Quality Initiative Workgroup. Acute Renal Failure-Definition, Outcome Measures, Animal Models, Fluid Therapy and Information Technology Needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care. Aug 2004;8(4):R204-212.
28. Endre, Z. H. and Westhuyzen, J. Early Detection of Acute Kidney Injury: Emerging New Biomarkers. Nephrology. (Carlton). 2008;13(2):91-98.
29. Uchino, S., Bellomo, R., Goldsmith, D., Bates, S., and Ronco, C. An Assessment of the RIFLE Criteria for Acute Renal Failure in Hospitalized Patients. Crit. Care Med. 2006;34(7):1913-1917.
30. Bosch, J. P. Renal Reserve: A Functional View of Glomerular Filtration Rate. Semin. Nephrol. 1995;15(5):381-385.
31. Herrera, J. and Rodríguez-Iturbe, B. Stimulation of Tubular Secretion of Creatinine in Health and in Conditions Associated with Reduced Nephron Mass. Evidence for a Tubular Functional Reserve. Nephrol. Dial. Transplant. 1998;13(3):623-629.
32. Jacobs, S. C, Ramey, J. R., Sklar, G. N., and Bartlett, S. T. Laparoscopic Kidney Donation From Patients Older Than 60 Years. J. Am. Coll. Surg. 2004;198(6):892-897.
33. Fehrman-Ekholm, I., Dunér, F., Brink, B., Tydén, G., and Elinder, C. G. No Evidence of Accelerated Loss of Kidney Function in Living Kidney Donors: Results From a Cross-Sectional Follow-up. Transplantation. 2001;15;72(3):444-449.
34. Coca, S. G. and Parikh, C. R. Urinary Biomarkers for Acute Kidney Injury: Perspectives on Translation. Clin. J. Am. Soc. Nephrol. 2008;3(2):481-190.
35. Price, M. Comparison of Creatinine Clearance to Inulin Clearance in the Determination of Glomerular Filtration Rate. J. Urol. 1972;107(3):339-340.
36. Gaspari, R, Mosconi, L., Vigano, G., Perico, G., Torre, L., Virotta, G., Bertoc-chi, C, Remuzzi, G., and Ruggenenti, P. Measurement of GFR With a Single Intravenous Injection of Nonradioactive Iothalamate. Kidney Int. 1992;41(4):1081-1084.
37. Prueksaritanont, T., Chen, M. L., and Chiou, W. L. Simple and Micro High-Performance Liquid Chromatographic Method for Simultaneous Determination of P-Aminohippuric Acid and Iothalamate in Biological Fluids. J. Chromatogr. 1984;306:89-97.
38. Boschi, S. and Marchesini, B. High-Performance Liquid Chromatographic Method for the Simultaneous Determination of Iothalamate and O-Iodohippu-rate. J. Chromatogr. 1981;224(1):139-143.
39. Back, S. E., Krutzén, E., and Nilsson-Ehle, P. Contrast Media As Markers for Glomerular Filtration: A Pharmacokinetic Comparison of Four Agents. Scand. J. Clin. Lab Invest. 1988;48(3):247-253.
40. Bróchner-Mortensen, J., Giese, J., and Rossing, N. Renal Inulin Clearance versus Total Plasma Clearance of 51Cr-EDTA. Scand. J. Clin. Lab. Invest. 1969;23(4):301-305.
41. Stevens, L. A. and Levey, A. S. Measurement of Kidney Function. Med. Clin. North Am. 2005;89(3):457-t73.
42. Tomlanovich, S., Golbetz, H., Perlroth, M., Stinson, E., and Myers, B. D. Limitations of Creatinine in Quantifying the Severity of Cyclosporine-Induced Chronic Nephropathy. Am. J. Kidney Dis. 1986;8(5):332-337.
43. Takubo, T., Kato, T., Kinami, J., Hanada, K., and Ogata, H. Effect of Trimethoprim on the Renal Clearance of Lamivudine in Rats. J. Pharm. Pharmacol. 2000;52(3):315-320.
44. Ixkes, M. C, Koopman, M. G., Van Acker, B. A., Weber, J. A., and Arisz, L. Ci-metidine Improves GFR-Estimation by the Cockcroft and Gault Formula. Clin. Nephrol. 1997;47(4):229-236.
45. Moran, S. M. and Myers, B. D. Course of Acute Renal Failure Studied by a Model of Creatinine Kinetics. Kidney Int. 1985;27(6):928-937.
46. Mussap, M. and Plebani, M. Biochemistry and Clinical Role of Human Cystatin C. Crit. Rev. Clin. Lab Sci. 2004;41(5-6):467-550.
47. Takuwa, S., Ito, Y, Ushijima, K., and Uchida, K. Serum Cystatin-C Values in Children by Age and Their Fluctuation During Dehydration. Pediatr. Int. 2002;44(1):28-31.
48. Risch, L., Herklotz, R., Blumberg, A., and Huber, A. R. Effects of Glucocorticoid Immunosuppression on Serum Cystatin C Concentrations in Renal Transplant Patients. Clin. Chem. 2001,47(11):2055-2059.
49. Madero, M., Sarnak, M. J., and Stevens, L. A. Serum Cystatin C As a Marker of Glomerular Filtration Rate. Curr. Opin. Nephrol. Hypertens. 2006;15(6):610-616.
50. Dharnidharka, V. R., Kwon, C, and Stevens, G. Serum Cystatin C Is Superior to Serum Creatinine As a Marker of Kidney Function: A Meta-Analysis. Am. J. Kidney Dis. 2002;40(2):221-226.
51. Shlipak, M. G., Praught, M. L., and Sarnak, M. J. Update on Cystatin C: New Insights Into the Importance of Mild Kidney Dysfunction. Curr. Opin. Nephrol. Hypertens. 2006;15(3):270-275.
52. Herget-Rosenthal, S., Marggraf, G., Hiising, J., Goring, E, Pietruck, E, Jans-sen, O., Philipp, T., and Kribben, A. Early Detection of Acute Renal Failure by Serum Cystatin C. Kidney Int. 2004;66(3):1115-1122.
53. Herget-Rosenthal, S., Pietruck, F, Volbracht, L., Philipp, T., and Kribben, A. Serum Cystatin C-A Superior Marker of Rapidly Reduced Glomerular Filtration After Uninephrectomy in Kidney Donors Compared to Creatinine. Clin. Nephrol. Jul 2005;64(1):41-46.
54. Séronie-Vivien, S., Delanaye, P., Piéroni, L., Mariat, C, Froissart, M., and Cristol, J. P. SFBC "Biology of Renal Function and Renal Failure" Working Group. Cystatin C: Current Position and Future Prospects. Clin. Chem. Lab. Med. 2008;46(12):1664-1686.
55. U.S. Food and Drug Administration Agency 510(K) Substantial Equivalence Determination Decision Summary Device Only, Rockville, USA (2007) http://www.fda.gov/cdrh/reviews/k041878.pdf.
56. Chesney, P. J., Davis, J. P., Purdy, W. K., Wand, P. J., and Chesney, R. W. Clinical Manifestations of Toxic Shock Syndrome. JAMA. 1981;246(7):741-748.
57. Diamond, J. R. and Yoburn, D. C. Nonoliguric Acute Renal Failure. Arch. Intern. Med. Oct 1982;142(10):1882-1884.
58. Richmond, J. M., Sibbald, W. J., Linton, A. M., and Linton, A. L. Patterns of Urinary Protein Excretion in Patients with Sepsis. Nephron. 1982;31(3):219-223.
59. Herget-Rosenthal, S., Poppen, D., Hiising, J., Marggraf, G., Pietruck, E, Jakob, H. G., Philipp, T, and Kribben, A. Prognostic Value of Tubular Proteinuria and Enzymuria in Nonoliguric Acute Tubular Necrosis. Clin. Chem. 2004;50(3):552-558.
60. Polkinghorne, K. R. Detection and Measurement of Urinary Protein. Curr. Opin. Nephrol. Hypertens. 2006;15(6):625-630.
61. Schmid, H., Henger, A., Cohen, C. D., Frach, K., Gróne, H. J., Schlóndorff, D., and Kretzler, M. Gene Expression Profiles of Podocyte-Associated Molecules As Diagnostic Markers in Acquired Proteinuric Diseases. J. Am. Soc. Nephrol. 2003;14(1l):2958-2966.
62. Guder, W. G. and Hofmann, W. Markers for the Diagnosis and Monitoring of Renal Tubular Lesions. Clin. Nephrol. 1992;38 Suppl l:S3-7.
63. D'Amico, G. and Bazzi, C. Pathophysiology of Proteinuria. Kidney Int. 2003;63(3):809-825.
64. Schieppati, A. and Remuzzi, G. Proteinuria and Its Consequences in Renal Disease. Acta Paediatr. Suppl. 2003;92(443):9-13.
65. Rodicio, J. L. and Ruilope, L. M. Assessing Renal Effects and Renal Protection. J. Hypertens. Suppl. 1995;13(4):S19-25.
66. Zomas, A., Anagnostopoulos, N., and Dimopoulos, M. A. Successful Treatment of Multiple Myeloma Relapsing After High-Dose Therapy and Autologous Transplantation with Thalidomide as a Single Agent. Bone Marrow Transplant. 2000;25(12):1319-1320.
67. Desikan, R., Veksler, Y, Raza, S., Stokes, B., Sabir, T, Li, Z. J., and Jagannath, S. Nephrotic Proteinuria Associated with High-Dose Pamidronate In Multiple Myeloma. Br. J. Haematol. 2002;119(2):496-499.
68. Koerbin, G., Taylor, L., Dutton, J., Marshall, K., Low, P., and Potter, J. M. Aminoglycoside Interference with the Dade Behring Pyrogallol Red-Molybdate Method for the Measurement of Total Urine Protein. Clin. Chem. 2001;47(12):2183-2184.
69. Loebstein, R. and Koren, G. Ifosfamide-Induced Nephrotoxicity in Children: Critical Review of Predictive Risk Factors. Pediatrics. Jun 1998;101(6):E8.
70. Guo, X. and Nzerue, C. How to Prevent, Recognize, and Treat Drug-Induced Nephrotoxicity. Cleve. Clin. J. Med. Apr 2002;69(4):289-297.
71. Benoehr, P., Krueth, P., Bokemeyer, C, Grenz, A., Osswald, H., and Hartmann, J. T. Nephroprotection by Theophylline in Patients with Cisplatin Chemotherapy: A Randomized, Single-Blinded, Placebo-Controlled Trial. J. Am. Soc. Nephrol. Feb 2005;16(2):452-458.
72. Peterson, P. A., Evrin, P. E., and Berggárd, I. Differentiation of Glomerular, Tubular, and Normal Proteinuria: Determinations of Urinary Excretion of Beta-2-Macroglobulin, Albumin, and Total Protein. J. Clin. Invest. Jul 1969;48(7):1189-1198.
73. Vaidya, V. S. and Bonventre, J. V. Mechanistic Biomarkers for Cytotoxic Acute Kidney Injury. Expert Opin. Drug Metab. Toxicol. 2006;2(5):697-713.
74. Gekle, M. Renal Albumin Handling: A Look at the Dark Side of the Filter. Kidney Int. 2007;71(6):479-81.
75. Tojo, A. and Endou, H. Intrarenal Handling of Proteins in Rats Using Fractional Micropuncture Technique. Am. J. Physiol. 1992;263(4 Pt 2):F601-606.
76. Sso, L. M., Sandoval, R. M., McKee, M., Osicka, T. M., Collins, A. B., Brown, D., Molitoris, B. A., and Comper, W. D. The Normal Kidney Filters Nephrotic Levels of Albumin Retrieved by Proximal Tubule Cells: Retrieval Is Disrupted in Nephrotic States. Kidney Int. 2007;71(6):504-513.
77. Christensen, E. I., Birn, H., Rippe, B., and Maunsbach, A. B. Controversies in Nephrology: Renal Albumin Handling, Facts, and Artifacts! Kidney Int. Nov 2007;72(10):1192-1194.
78. Greive, K. A., Nikolic-Paterson, D. J., Guimaraes, M. A., Nikolovski, J., Pratt, L. M., Mu, W., Atkins, R. C, and Comper, W. D. Glomerular Permselectivity Factors Are Not Responsible for the Increase in Fractional Clearance of Albumin in Rat Glomerulonephritis. Am. J. Pathol. 2001;159(3):1159-1170.
79. Lane, J. T., Ford, T. C, Larson, L. R., Chambers, W. A., and Lane, P. H. Acute Effects of Different Intensities of Exercise in Normoalbuminuric/Normotensive Patients with Type 1 Diabetes. Diabetes Care. 2004;27(1):28-32.
80. Bakris, G. Inclusion of Albuminuria in Hypertension and Heart Guidelines. Kidney Int. Suppl. 2004;(92):S 124-125.
81. Weir, M. R. Microalbuminuria and Cardiovascular Disease. Clin. J. Am. Soc. Nephrol. 2007;2(3):581-590.
82. Sarafidis, P. A. Proteinuria: Natural Course, Prognostic Implications and Therapeutic Considerations. Minerva Med. Dec 2007;98(6):693-711.
83. Selby, J. V., Karter, A. J., Ackerson, L. M., Ferrara, A., and Liu, J. Developing a Prediction Rule from Automated Clinical Databases to Identify High-Risk Patients in a Large Population with Diabetes. Diabetes Care. Sep 2001;24(9):1547-1555.
84. Rigden, S. P., Barratt, T. M., Dillon, M. J., Kind, P. R., De Leval, M., Stark, J. Renal Function Following Cardiopulmonary Bypass Surgery in Children: A Randomized Comparison of the Effects of Gentamicin and Cloxacillin with Ce-phalothin. Clin. Nephrol. May 1983;19(5):228-231.
85. Pfaller, W., Thorwartl, U., Nevinny-Stickel, M., Krall, M., Schober, M., Joan-nidis, M., and Hobisch, A. Clinical Value of Fructose 1,6 Bisphosphatase in Monitoring Renal Proximal Tubular Injury. Kidney Int. Suppl. 1994;47:S68-75.
86. Metz-Kurschel, U., Kurschel, E., Niederle, N., and Aulbert, E. Investigations on the Acute and Chronic Nephrotoxicity of the New Platinum Analogue Carbopla-tin. J. Cancer Res. Clin. Oncol. 1990;116(2):203-206.
87. Heney, D., Wheeldon, J., Rushworth, P., Chapman, C, Lewis, I. J., and Bailey, C. C. Progressive Renal Toxicity Due to Ifosfamide. Arch. Dis. Child. 1991;66(8):966
88. La Manna, G., Virzi, S., Deraco, M., Capelli, I., Accorsi, A., Dalmastri, V., Comai, G., Bonomi, S., Grassi, A., Selva, S., Feliciangeli, G., Scolari, M., and Stefoni, S. Tubular Dysfunction After Peritonectomy and Chemohyperthermic Treatment with Cisplatin. In Vivo. 2006;20(6A):703-706.
89. Thielemans, N., Lauwerys, R., and Bernard, A. Competition between Albumin and Low-Molecular-Weight Proteins for Renal Tubular Uptake in Experimental Nephropathies. Nephron. 1994;66(4):453--58.
90. Davey, P. G. and Gosling, P. Beta 2-Microglobulin Instability in Pathological Urine. Clin. Chem. Jun 1982;28(6):1330-1333.
91. Fernandez, F, De Miguel, M. D., Barrio, V., and Mallol, J. Beta-2-Microglob-ulin As an Index of Renal Function After Cardiopulmonary Bypass Surgery in Children. Child Nephrol. Urol. 1988/1989;9(6):326-330.
92. Dehne, M. G., Boldt, J., Heise, D., Sablotzki, A., and Hempelmann, G. Tamm-Horsfall Protein, Alpha-1- and Beta-2-Microglobulin As Kidney Function Markers in Heart Surgery. Anaesthesist. 1995;44(8):545-551.
93. Schaub, S., Wilkins, J. A., Antonovici, M., Krokhin, O., Weiler, T, Rush, D., and Nickerson, P. Proteomic-Based Identification of Cleaved Urinary Beta2-Mi- croglobulin As a Potential Marker for Acute Tubular Injury in Renal Allografts. Am. J. Transplant. 2005;5(4 Pt l):729-738.
94. Gatanaga, H., Tachikawa, N., Kikuchi, Y., Teruya, K., Genka, I., Honda, M., Tanuma, J., Yazaki, H., Ueda, A., Kimura, S., and Oka, S. Urinary Beta2-Micro-globulin As a Possible Sensitive Marker for Renal Injury Caused by Tenofovir Disoproxil Fumarate. AIDS Res. Hum. Retroviruses. Aug 2006;22(8):744-748.
95. Schentag, J. J. and Plaut, M. E. Patterns of Urinary Beta 2-Microglobulin Excretion by Patients Treated with Aminoglycosides. Kidney Int. May 1980;17(5):654-661.
96. Jones, B. R., Bhalla, R. B., Mladek, J., Kaleya, R. N., Gralla, R. J., Alcock, N. W., Schwartz, M. K., Young, C. W., and Reidenberg, M. M. Comparison of Methods of Evaluating Nephrotoxicity of Cis-Platinum. Clin. Pharmacol. Ther. Apr 1980;27(4):557-562.
97. Tirelli, A. S., Colombo, N., Cavanna, G., Mangioni, C, and Assael, B. M. Follow-up Study of Enzymuria and Beta 2-Microglobulinuria During Cis-Platinum Treatment. Eur. J. Clin. Pharmacol. 1985;29(3):313-318.
98. Latt, D., Weiss, J. B., and Jayson, M. I. Beta 2-Microglobulin Levels in Serum and Urine of Rheumatoid Arthritis Patients on Gold Therapy. Ann. Rheum. Dis. Apr 1981;40(2):157-160.
99. Bagshaw, S. M., Langenberg, C, Haase, M., Wan, L., May, C. N., and Bellomo, R. Urinary Biomarkers in Septic Acute Kidney Injury. Intensive Care Med. 2007;33(7):1285-1296.
100. Herget-Rosenthal, S., Poppen, D., Hiising, J., Marggraf, G., Pietruck, F, Jakob, H. G., Philipp, T., and Kribben, A. Prognostic Value of Tubular Proteinuria and Enzymuria in Nonoliguric Acute Tubular Necrosis. Clin. Chem. 2004;50(3):552-558.
101. Herget-Rosenthal, S., Van Wijk, J. A., Brócker-Preuss, A., and Bókenkamp, A. Increased Urinary Cystatin C Reflects Structural and Functional Renal Tubular Impairment Independent of Glomerular Filtration Rate. Clin. Biochem. 2007;40(13-14):946-951.
102. Conti, M., Moutereau, S., Zater, M., Lallali, K., Durrbach, A., Manivet, P., Es-chwége, P., and Lorie, S. Urinary Cystatin C As a Specific Marker of Tubular Dysfunction. Clin. Chem. Lab Med. 2006;44(3):288-291.
103. Tenstad, O., Roald, A. B., Grubb A., and Aukland, K. Renal Handling of Radiolabelled Human Cystatin C in the Rat. Scand. J. Clin. Lab Invest. Aug 1996;56(5):409-tl4.
104. Collé, A., Tavera. C, Laurent, P., Leung-Tack, J., and Girolami, J. P. Direct Radioimmunoassay of Rat Cystatin C: Increased Urinary Excretion of This Cysteine Proteases Inhibitor During Chromate Nephropathy. J. Immunoassay. 1990;11(2):199-214.
105. Uchida, K. and Gotoh, A. Measurement of Cystatin-C and Creatinine in Urine. Clin. Chim.Acta. 2002;323(1-2):121-128.
106. Tkaczyk, M., Nowicki, M., and Lukamowicz, J. Increased Cystatin C Concentration in Urine of Nephrotic Children. Pediatr. Nephrol. 2004;19(11):1278-1280.
107. Sadzuka, Y., Shimizu, Y, and Takino, Y Role of Glutathione S-Transferase Isoenzymes in Cisplatin-Induced Nephrotoxicity in the Rat. Toxicol. Lett. 1994;70(2):211-222.
108. Harpur, E., Schuster, K., Betton, G., Bounous, D., Ennulat, D., Riefke, B., Myle-craine, L., Pettit, S., Hoffman, D., Gautier, J., and Beushausen, S. Comparative Performance of Novel Marker of Nephrotoxicity in the Rat. Poster, http://www. argutusmed.com/_fileupload/nephrotoxicity%20poster.pdf.
109. Kharasch, E. D., Thorning, D., Garton, K., Hankins, D. C, and Kilty, C. G. Anesthesiology. 1997;86(1):160-171.
110. Goldberg, M. E., Cantillo, J., Gratz, I., Deal, E., Vekeman, D., McDougall, R., Afshar, M., Zafeiridis, A., and Larijani, G. Dose of Compound A, Not Sevo-flurane, Determines Changes in the Biochemical Markers of Renal Injury in Healthy Volunteers. Anesth. Analg. 1999;88(2):437-t45.
111. Pai, M. P., Norenberg, J. P., Telepak, R. A., Sidney, D. S., and Yang, S. Assessment of Effective Renal Plasma Flow, Enzymuria, and Cytokine Release in Healthy Volunteers Receiving a Single Dose of Amphotericin T Desoxycholate. Antimicrob. Agents Chemother. 2005;49(9):3784-3788.
112. Sundberg, A. G., Appelkvist, E. L., Backman, L., and Dallner, G. Urinary Pi-Class Glutathione Transferase As an Indicator of Tubular Damage in the Human Kidney. Nephron. 1994;67(3):308-316.
113. El-Safty, I. M. A., Gadallah, M., and Shouman, A. E. Effect of Silica Exposure on Urinary Excretion of Copper and Zinc. Am. J. Med. Sci. 2003;326(3):122-127.
114. Cawood, T., Bashir, M., Brady, J., Murray, B., and O'Shea, D. The Potential Use of Urinary Biomarkers for Detecting and Localizing Injury to the Nephron in Diabetes. Poster, http://www.argutusmed.com/_fileupload/diabetes%20poster%20 -%20June%202008%20ISN.pdf.
115. Bashir, M., Cawood, T, Brady, J., Murray, B., and O'Shea, D. The Detection of Obesity-Related Nephropathy Using Novel Urinary Biomarkers. http://www.ar-gutusmed.com/_fileupload/Image/obesity%20related%20nephrop athy%20post-er%20-%20june%202008.pdf.
116. Koyner, J. L., Schuster, K., Trevino, S., and Murray, P. T. Alpha Glutathione S-Transferase and Pi Glutathione S-Transferase are Novel Biomarkers of Acute Kidney Injury Following Adult Cardiac Surgery, http://www.argutusmed.eom/_fileupload/AKI%20in%20cardiac%20surgery%20pos ter%20-%202008%20ASN%20renal%20week.pdf.
117. Westhuyzen, J., Endre, Z. H., Reece, G., Reith, D. M., Saltissi, D., and Morgan, T. J. Measurement of Tubular Enzymuria Facilitates Early Detection of Acute Renal Impairment in the Intensive Care Unit. Nephrol. Dial. Transplant. 2003;18(3):543-551.
118. Price, R. G. The Role of NAG (N-Acetyl-Beta-D-Glucosaminidase) in the Diagnosis of Kidney Disease Including the Monitoring of Nephrotoxicity. Clin. Nephrol. 1992;38 Suppl l:S14-9.
119. Skálová, S. The Diagnostic Role of Urinary N-Acetyl-Beta-D-Glucosaminidase (NAG) Activity in the Detection of Renal Tubular Impairment. Acta Medica. (Hradec Kralove). 2005;48(2):75-80.
120. Emeigh Hart, S. G. Assessment of Renal Injury In Vivo. J. Pharmacol. Toxicol. Methods. 2005;52(1):30-45.
121. Ascione, R., Lloyd, C. T, Underwood, M. J., Gomes, W. J., and Angelini, G. D. On-Pump versus Off-Pump Coronary Revascularization: Evaluation of Renal Function. Ann. Thorac. Surg. 1999;68(2):493-98.
122. Liangos, O., Perianayagam, M. C, Vaidya, V. S., Han, W. K., Wald, R., Tighio-uart, H., Mackinnon, R. W., Li, L., Balakrishnan, V. S., Pereira, B. J., Bonven-tre, J. V, and Jaber, B. L. Urinary N-Acetyl-Beta-(D)-Glucosaminidase Activity and Kidney Injury Molecule-1 Level Are Associated with Adverse Outcomes in Acute Renal Failure. J. Am. Soc. Nephrol. 2007;18(3):904-912.
123. Wiley, R. A., Choo, H. Y., and Traiger, G. J. The Effect of Nephrotoxic Furans on Urinary N-Acetylglucosaminidase Levels in Mice. Toxicol. Lett. Nov 1982;14(1-2):93-96.
124. Bonventre, J. V. Diagnosis of Acute Kidney Injury: From Classic Parameters to New Biomarkers. Contrib. Nephrol. 2007;156:213-219.
125. Bondiou, M. T., Bourbouze, R., Bernard, M., Percheron, F., Perez-Gonzalez, N., and Cabezas, J. A. Inhibition of A and T N-Acetyl-Beta-D-Glucosaminidase Urinary Isoenzymes by Urea. Clin. Chim. Acta. 1985;149(1):67-73.
126. Iqbal, M. P., Ali, A. A., Waqar, M. A., and Mehboobali, N. Urinary N-Acetyl-Beta-D-Glucosaminidase in Rheumatoid Arthritis. Exp. Mol. Med. Sep 30, 1998;30(3):165-169.
127. Tominaga, M., Fujiyama, K., Hoshino, T., Tanaka, Y., Takeuchi, T., Honda, M., Mokuda, O., Ikeda, T., and Mashiba, H. Urinary N-Acetyl-Beta-D-Glucosamin-idase in the Patients with Hyperthyroidism. Horm. Metab. Res. 1989;21(8):438-40.
128. Higuchi, H., Sumita, S., Wada, H., Ura, T., Ikemoto, T., Nakai, T., Kanno, M., and Satoh, T. Effects of Sevoflurane and Isoflurane on Renal Function and on Possible Markers of Nephrotoxicity. Anesthesiology. 1998;89(2):307-322.
129. Mukherjea, D., Whitworth, C. A., Nandish, S., Dunaway, G. A., Rybak, L. P., and Ramkumar, V. Expression of the Kidney Injury Molecule 1 in the Rat Cochlea and Induction by Cisplatin. Neuroscience. May 12, 2006;139(2):733-740.
130. Zhang, Z., Humphreys, B. D., and Bonventre, J. V. Shedding of the Urinary Biomarker Kidney Injury Molecule-1 (KIM-1) Is Regulated by MAP Kinases and Juxtamembrane Region. Am. Soc. Nephrol. 2007;18(10):2704-2714.
131. Van Timmeren, M. M., Bakker, S. J., Vaidya, V. S., Bailly, V., Schuurs, T. A., Damman, J., Stegeman, C. A., Bonventre, J. V., and Van Goor, H. Tubular Kidney Injury Molecule-1 in Protein-overload Nephropathy. Am. J. Physiol. Renal Physiol. 2006;291(2):F456-464.
132. Ichimura, T., Bonventre, J. V., Bailly, V, Wei, H., Hession, C. A., Cate, R. L., and Sanicola, M. Kidney Injury Molecule-1 (KIM-1), a Putative Epithelial Cell Adhesion Molecule Containing a Novel Immunoglobulin Domain, Is Up-Regulated in Renal Cells After Injury. J. Biol. Chem. 1998;273(7):4135-4142.
133. Kuehn, E. W., Park, K. M., Somlo, S., and Bonventre, J. V. Kidney Injury Molecule-1 Expression in Murine Polycystic Kidney Disease. Am. J. Physiol. Renal Physiol. 2002;283(6):F1326-336.
134. Ichimura, T., Hung, C. C, Yang, S.A., Stevens, J. L., and Bonventre, J. V. Kidney Injury Molecule-1:A Tissue snd Urinary Biomarker for Nephrotoxicant-Induced Renal Injury. Am. J. Physiol. Renal Physiol. 2004;286(3):F552-563.
135. Prozialeck, W. C, Edwards, J. R., Vaidya, V. S., and Bonventre, J. V. Preclinical Evaluation of Novel Urinary Biomarkers of Cadmium Nephrotoxicity. Toxicol. Appl. Pharmacol. 2009, In Press.
136. Prozialeck, W. C, Vaidya, V. S., Liu, J., Waalkes, M. P., Edwards, J. R., Lamar, P. C, Bernard, A. M., Dumont, X., and Bonventre, J. V. Kidney Injury Molecule-1 Is an Early Biomarker of Cadmium Nephrotoxicity. Kidney Int. 2007;72(8):985-993.
137. Jost, G., Pietsch, H., Sommer, J., Sandner, P., Lengsfeld, P., Seidensticker, P., Lehr, S., Hiitter, J., and Sieber, M. A. Retention of Iodine and Expression of Biomarkers for Renal Damage in the Kidney After Application of Iodinated Contrast Media in Rats. Invest. Radiol. 2009;44(2):114-123.
138. Zhou, Y., Vaidya, V. S., Brown, R. P., Zhang, J., Rosenzweig, B. A., Thompson, K. L., Miller, T. J., Bonventre, J. V, and Goering, P. L. Comparison of Kidney Injury Molecule-1 and Other Nephrotoxicity Biomarkers in Urine and Kidney Following Acute Exposure to Gentamicin, Mercury, and Chromium. Toxicol. Sci. 2008;101(1):159-170.
139. Rached, E., Hoffmann, D., Blumbach, K., Weber, K., Dekant, W., and Mally, A. Evaluation of Putative Biomarkers of Nephrotoxicity After Exposure to Ochratoxin A In Vivo and In Vitro. Toxicol. Sci. 2008;103(2):371-381.
140. Pérez-Rojas, J., Blanco, J. A., Cruz, C, Traillo, J., Vaidya, V. S., Uribe, N., Bonventre, J. V, Gamba, G., and Bobadilla, N. A. Mineralocorticoid Receptor Blockade Confers Renoprotection in Preexisting Chronic Cyclosporine Nephrotoxicity. Am. J. Physiol. Renal Physiol. 2007;292(1):F131-139.
141. Han, W. K., Waikar, S. S., Johnson, A., Betensky, R. A., Dent, C. L., Devarajan, P., and Bonventre, J. V Urinary Biomarkers in the Early Diagnosis of Acute Kidney Injury. Kidney Int. 2008;73(7):863-869.
142. Liangos, O., Perianayagam, M. C, Vaidya, V. S., Han, W. K., Wald, R., Tighio-uart, H., MacKinnon, R. W., Li, L., Balakrishnan, V. S., Pereira, B. J., Bonventre, J. V, and Jaber, B. L. Urinary N-Acetyl-Beta-(D)-Glucosaminidase Activity and Kidney Injury Molecule-1 Level Are Associated with Adverse Outcomes in Acute Renal Failure. J. Am. Soc. Nephrol. 2007;18(3):904-912.
143. Waanders, K, Vaidya, V. S., Van Goor, H., Leuvenink, H., Damman, K., Hamming, I., Bonventre, J. V, Vogt, L., and Navis, G. Effect of Renin-Angiotensin-Aldosterone System Inhibition, Dietary Sodium Restriction, and/or Diuretics on Urinary Kidney Injury Molecule 1 Excretion in Nondiabetic Proteinuric Kidney Disease: A Post Hoc Analysis of a Randomized Controlled Trial. Am. J. Kidney Dis. 2009;53(1):1-1.
144. Han, W. K., Bailly, V, Abichandani, R., Thadhani, R., and Bonventre, J. V Kidney Injury Molecule-1 (KIM-1):A Novel Biomarker for Human Renal Proximal Tubule Injury. Kidney Int. 2002;62(1):237-244.
145. Van Timmeren, M. M., Van Den Heuvel, M. C, Bailly, V, Bakker, S. J., Van Goor, H., and Stegeman, C. A. Tubular Kidney Injury Molecule-1 (KIM-1) in Human Renal Disease. J. Pathol. Jun 2007;212(2):209-217.
146. Zhang, P. L., Rothblum, L. I., Han, W. K., Blasick, T. M., Potdar, S., and Bonventre, J. V. Kidney Injury Molecule-1 Expression in Transplant Biopsies Is a Sensitive Measure of Cell Injury. Kidney Int. 2008;73(5):608-614.
147. Van Timmeren, M. M., Vaidya, V. S., Van Ree, R. M., Oterdoom, L. H., De Vries, A. P., Gans, R. O., Van Goor, H., Stegeman, C. A., Bonventre, J. V, and Bakker, S. J. High Urinary Excretion of Kidney Injury Molecule-1 Is an Independent Predictor of Graft Loss in Renal Transplant Recipients. Transplantation. 2007 27;84(12):1625-1630.
148. Rosenberg, M. E. and Silkensen, J. Clusterin and the Kidney. Exp. Nephrol. 1995;3(1):9-14.
149. Kharasch, E. D., Schroeder, J. L., Bammler, T., Beyer, R., and Srinouan-prachanh, S. Gene Expression Profiling of Nephrotoxicity from the Sevoflu-rane Degradation Product Fluoromethyl-2,2-Difluoro-l-(Trifluoromethyl)Vinyl Ether ("Compound A") in Rats. Toxicol. Sci. 2006;90(2):419-131.
150. Rached, E., Hoffmann, D., Blumbach, K., Weber, K., Dekant, W., and Mally, A. Evaluation of Putative Biomarkers of Nephrotoxicity after Exposure to Ochratoxin A In Vivo and In Vitro. Toxicol. Sci. 2008;103(2):371-381.
151. Correa-Rotter, R., Ibarra-Rubio, M. E., Schwochau, G., Cruz, C, Silkensen, J. R., Pedraza-Chaverri, J., Chmielewski, D., and Rosenberg, M. E. Induction of Clusterin in Tubules of Nephrotic Rats. J. Am. Soc. Nephrol. 1998;9(1):33-37.
152. Tsuchiya, Y., Tominaga, Y., Matsubayashi, K., Jindo, T., Furuhama, K., and Suzuki, K. T. Investigation on Urinary Proteins and Renal Mrna Expression in Canine Renal Papillary Necrosis Induced by Neflracetam. Arch. Toxicol. 2005;79(9):500-507.
153. Yoshida, T., Kurella, M., Beato, R, Min, H., Ingelfinger, J. R., Stears, R. L., Swinford, R. D., Gullans, S. R., and Tang, S. S. Monitoring Changes in Gene Expression in Renal Ischemia-Reperfusion in the Rat. Kidney Int. 2002;61(5):1646-1654.
154. Correa-Rotter, R., Hostetter, T. H., Manivel, J. C, Eddy, A. A., and Rosenberg, M. E. Intrarenal Distribution of Clusterin Following Reduction of Renal Mass. Kidney Int. 1992;41(4):938-950.
155. Ishii, A., Sakai, Y, and Nakamura, A. Molecular Pathological Evaluation of Clusterin in a Rat Model of Unilateral Ureteral Obstruction as a Possible Bio-marker of Nephrotoxicity. Toxicol. Pathol. 2007;35(3):376-382.
156. Hidaka, S., Kranzlin, B., Gretz, N., and Witzgall, R. Urinary Clusterin Levels in the Rat Correlate with the Severity of Tubular Damage and May Help to Differentiate Between Glomerular and Tubular Injuries. Cell Tissue Res. 2002;310(3):289-296.
157. Rosenberg, M. E. and Silkensen, J. Clusterin: Physiologic and Pathophysiologic Considerations. Int. J. Biochem. Cell Biol. Jul 1995;27(7):633-645.
158. Ghiggeri, G. M., Bruschi, M., Candiano, G., Rastaldi, M. P., Scolari, R, Pas-serini, P., Musante, L., Pertica, N., Caridi, G., Ferrario, R, Perfumo, R, and Ponti-celli, C. Depletion of Clusterin in Renal Diseases Causing Nephrotic Syndrome. Kidney Int. 2002;62(6):2184-2194.
159. Nielsen, B. S., Borregaard, N., Bundgaard, J. R., Timshel, S., Sehested, M., and Kjeldsen, L. Induction of NGAL Synthesis in Epithelial Cells of Human Colorectal Neoplasia and Inflammatory Bowel Diseases. Gut. 1996;38(3):414-420.
160. Cowland, J. B. and Borregaard, N. Molecular Characterization and Pattern of Tissue Expression of the Gene for Neutrophil Gelatinase-Associated Lipocalin From Humans. Genomics. 1997;45(1):17-23.
161. Mishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., and Devarajan, P. Identification of Neutrophil Gelatinase-Associated Lipocalin As a Novel Early Urinary Biomarker for Ischemic Renal Injury. J. Am. Soc. Nephrol. 2003;14(10):2534-2543.
162. Mishra, J., Mori, K., Ma, Q., Kelly, C, Barasch, J., and Devarajan, P. Neutrophil Gelatinase-Associated Lipocalin: A Novel Early Urinary Biomarker for Cispla-tin Nephrotoxicity. Am. J. Nephrol. May/Jun 2004;24(3):307-315.
163. Mishra, J., Dent, C, Tarabishi, R., Mitsnefes, M. M., Ma, Q., Kelly, C, Ruff, S. M., Zahedi, K., Shao, M., Bean, J., Mori, K., Barasch, J., and Devarajan, P. Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Renal Injury After Cardiac Surgery. Lancet. 2008;365(9466):1231-1238.
164. Wagener, G., Jan, M., Kim, M., Mori, K., Barasch, J. M., Sladen, R. N., and Lee, H. T. Association Between Increases in Urinary Neutrophil Gelatinase-Associated Lipocalin and Acute Renal Dysfunction After Adult Cardiac Surgery. Anesthesiology. 2006;105(3):485-491.
165. Makris, K., Markou, N., Evodia, E., Dimopoulou, E., Drakopoulos, I., Ntetsika, K., Rizos, D., Baltopoulos, G., and Haliassos, A. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) As an Early Marker of
166. Bachorzewska-Gajewska, H., Malyszko, J., Sitniewska, E., Malyszko, J. S., and Dobrzycki, S. Neutrophil-Gelatinase-Associated Lipocalin and Renal Function After Percutaneous Coronary Interventions. Am. J. Nephrol. 2006;26(3):287-292.
167. Bachorzewska-Gajewska, H., Malyszko, J., Sitniewska, E., Malyszko, J. S., Pawlak, K., Mysliwiec, M., Lawnicki, S., Szmitkowski, M., and Dobrzycki, S. Could Neutrophil-Gelatinase-Associated Lipocalin and Cystatin C Predict the Development of Contrast-Induced Nephropathy After Percutaneous Coronary Interventions in Patients with Stable Angina and Normal Serum Creatinine Values? Kidney Blood Press. Res. 2007;30(6):408-415.
168. Hirsch, R., Dent, C, Pfriem, H., Allen, J., and Beekman, R. H., Ill, Ma, Q., Das-trala, S., Bennett, M., Mitsnefes, M., and Devarajan, P. NGAL Is an Early Predictive Biomarker of Contrast-Induced Nephropathy in Children. Pediatr. Nephrol. Dec 2007;22(12):2089-2095.
169. Bolignano, D., Coppolino, G., Campo, S., Aloisi, C, Nicocia, G., Frisina, N., and Buemi, M. Neutrophil Gelatinase-Associated Lipocalin in Patients with Autosomal-Dominant Polycystic Kidney Disease. Am. J. Nephrol. 2007;27(4):373-378.
170. Ding, H., He, Y., Li, K., Yang, J., Li, X., Lu, R., and Gao, W. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Is an Early Biomarker for Renal Tubulointerstitial Injury in Iga Nephropathy. Clin. Immunol. May 2007;123(2):227-234.
171. Bolignano, D., Coppolino, G., Campo, S., Aloisi, C, Nicocia, G., Frisina, N., and Buemi, M. Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Is Associated with Severity of Renal Disease in Proteinuric Patients. Nephrol. Dial. Transplant. 2008;23(1):414-416.
172. Bolignano, D., Coppolino, G., Lacquaniti, A., Nicocia, G., and Buemi, M. Pathological and Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin in Macroproteinuric Patients with Worsening Renal Function. Kidney Blood Press. Res. 2008;31(4):274-279.
173. Bolignano, D., Lacquaniti, A., Coppolino, G., Donato, V, Fazio, M. R., Nicocia, G., and Buemi, M. Neutrophil Gelatinase-Associated Lipocalin As An Early Biomarker of Nephropathy in Diabetic Patients. Kidney Blood Press. Res. 2009;32(2):91-98.
174. Bolignano, D., Donato, V, Coppolino, G., Campo, S., Buemi, A., Lacquaniti, A., and Buemi, M. Neutrophil Gelatinase-Associated Lipocalin (NGAL) As a Marker of Kidney Damage. Am. J. Kidney Dis. 2008;52(3):595-605.
175. Abdelmagid, S. M., Barbe, M. F, Rico, M. C, Salihoglu, S., Arango-Hisijara, I., Selim, A. H., Anderson, M. G., Owen, T. A., Popoff, S. N., and Safadi, F. F. Osteoactivin, an Anabolic Factor That Regulates Osteoblast Differentiation and Function. Exp. Cell. Res. 2008;314(13):2334-2351.
176. Weterman, M. A., Ajubi, N., Van Dinter, I. M., Degen, W. G., Van Muijen, G. N., Ruitter, D. J., and Bloemers, H. P. Nmb, a Novel Gene, Is Expressed in Low-Metastatic Human Melanoma Cell Lines and Xenografts. Int. J. Cancer. 1995;60(1):73-81.
177. Selim, A. A. Osteoactivin Bioinformatic Analysis: Prediction of Novel Functions, Structural Features, and Modes of Action. Med. Sci. Monit. 2009;15(2):MT19-33.
178. Nakamura, A., Ishii, A, Ohata, C, and Komurasaki, T. Early Induction of Osteoactivin Expression in Rat Renal Tubular Epithelial Cells After Unilateral Ureteral Obstruction. Exp. Toxicol. Pathol. 2007;59(1):53-59.
179. Onaga, M., Ido, A., Hasuike, S., Uto, H., Moriuchi, A., Nagata, K., Hori, T., Hayash, K., and Tsubouchi, H. Osteoactivin Expressed During Cirrhosis Development in Rats Fed a Choline-Deficient, L-Amino Acid-Defined Diet, Accelerates Motility of Hepatoma Cells. J. Hepatol. 2003;39(5):779-785.
180. Xie, Y., Sakatsume, M., Nishi, S., Narita, I., Arakawa, M, and Gejyo, F. Expression, Roles, Receptors, and Regulation of Osteopontin in the Kidney. Kidney Int. 2001;60(5):1645-1657.
181. Giachelli, C. M., Lombardi, D., Johnson, R. J., Murry, C. E., and Almeida, M. Evidence for a Role of Osteopontin in Macrophage Infiltration in Response to Pathological Stimuli In Vivo. Am. J. Pathol. Feb 1998;152(2):353-358.
182. Hudkins, K. L., Giachelli, C. M., Cui, Y., Couser, W. G., Johnson, R. J., and Alp-ers, C. E. Osteopontin Expression in Fetal and Mature Human Kidney. J. Am. Soc. Nephrol. 1999;10(3):444-57.
183. Wang, E. J., Snyder, R. D., Fielden, M. R., Smith, R. J., and Gu, Y. Z. Validation of Putative Genomic Biomarkers of Nephrotoxicity in Rats. Toxicology. 2008;246(2-3):91-100.
184. Rached, E., Hoffmann, D., Blumbach, K., Weber, K., Dekant, W., and Mally, A. Evaluation of Putative Biomarkers of Nephrotoxicity After Exposure to Ochra-toxin A In Vivo and In Vitro. Toxicol. Sci. Jun 2008;103(2):371-381.
185. Xie, Y, Nishi, S., Iguchi, S., Imai, N., Sakatsume, M., Saito, A., Ikegame, M., Iino, N., Shimada, H., Ueno, M., Kawashima, H., Arakawa, M., and Gejyo, F. Expression of Osteopontin in Gentamicin-Induced Acute Tubular Necrosis and Its Recovery Process. Kidney Int. Mar 2001;59(3):959-974.
186. Hudkins, K. L., Giachelli, C. M., Eitner, F., Couser, W. G., Johnson, R. J., and Alpers, C. E. Osteopontin Expression in Human Crescentic Glomerulonephritis. Kidney Int. Jan 2000;57(1):105-116.
187. Hudkins, K. L., Le, Q. C, Segerer, S., Johnson, R. J., Davis, C. L., Giachelli, C. M., and Alpers, C. E. Osteopontin Expression in Human Cyclosporine Toxicity. Kidney Int. Aug 2001;60(2):635-640.
188. Thomas, S. E., Lombardi, D., Giachelli, C, Bohle, A., and Johnson, R. J. Osteopontin Expression, Tubulointerstitial Disease, and Essential Hypertension. Am. J. Hypertens. 1998;11(8 Pt 1):954-961.
189. Ramankulov, A., Lein, M., Kristiansen, G., Meyer, H. A., Loening, S. A., and Jung, K. Elevated Plasma Osteopontin As Marker for Distant Metastases and Poor Survival in Patients With Renal Cell Carcinoma. Cancer Res. Clin. Oncol. Sep 2007;133(9):643-652.
190. Yang, A., Trajkovic, D., Illanes, O., and Ramiro-Ibáñez, F. Clinicopathological and Tissue Indicators of Para-Aminophenol Nephrotoxicity in Sprague-Dawley Rats. Toxicol. Pathol. 2007;35(4):521-532.
191. Mezzano, S. a., Droguett, M. A., Burgos, M. E., Ardiles, L. G., Aros, C. A., Caorsi, I., and Egido, J. Overexpression of Chemokines, Fibrogenic Cytokines, and Myofibroblasts in Human Membranous Nephropathy. Kidney Int. 2000;57(1):147-158.
192. Okada, H., Moriwaki, K., Konishi, K., Kobayashi, T., Sugahara, S., Nakamoto, H., Saruta, T., and Suzuki, H. Tubular Osteopontin Expression in Human Glomerulonephritis and Renal Vasculitis. Am. J. Kidney Dis. 2000;36(3):498-506.
193. Verstrepen, W. A., Persy, V. P., Verhulst, A., Dauwe, S., and De Broe, M. E. Renal Osteopontin Protein and Mrna Upregulation During Acute Nephrotoxicity in the Rat. Nephrol. Dial. Transplant. 2001;16(4):712-724.
194. Davis, J. W., II, Goodsaid, F. M, Bral, C. M., Obert, L. A., Mandakas, G., Garner, C. E., II, Collins, N. D., Smith, R. J., and Rosenblum, I. Y. Quantitative Gene Expression Analysis in a Nonhuman Primate Model of Antibiotic-Induced Nephrotoxicity. Toxicol. Appl. Pharmacol. 2004;200(1):16-26.
195. Kharasch, E. D., Schroeder, J. L., Bammler, T., Beyer, R., and Srinouan-prachanh, S. Gene Expression Profiling of Nephrotoxicity From the Sevoflu-rane Degradation Product Fluoromethyl-2,2-Difluoro-l-(Trifluoromethyl)Vinyl Ether ("Compound A") in Rats. Toxicol. Sci. Apr 2006;90(2):419-431.
196. Gang, X., Ueki, K., Kon, S., Maeda, M., Naruse, T., and Nojima, Y. Reduced Urinary Excretion of Intact Osteopontin in Patients with Iga Nephropathy. Am. J. Kidney Dis. 2001;37(2):374-379.
197. Maatman, R. G., Van De Westerlo, E. M, Van Kuppevelt, T. H., and Veerkamp, J. H. Molecular Identification of the Liver and the Heart-Type Fatty Acid-Binding Proteins in Human and Rat Kidney. Use of the Reverse Transcriptase Polymerase Chain Reaction. Biochem. J. 1992;288(Pt l):285-290.
198. Sweetser, D. A., Heuckeroth, R. O., and Gordon, J. I. The Metabolic Significance of Mammalian Fatty-Acid-Binding Proteins: Abundant Proteins in Search of a Function. Annu. Rev. Nutr. 1987;7:337-359.
199. Negishi, K., Noiri, E., Sugaya, T., Li, S., Megyesi, J., Nagothu, K., and Portilla, D. A Role of Liver Fatty Acid-Binding Protein in Cisplatin-Induced Acute Renal Failure. Kidney Int. 2007;72(3):348-358.
200. Nakamura, T., Sugaya, T., Node, K., Ueda, Y, and Koide, H. Urinary Excretion of Liver-Type Fatty Acid-Binding Protein in Contrast Medium-Induced Nephropathy. Am. J. Kidney Dis. 2006;47(3):439-44.
201. Nakamura, K., Ito, K., Kato, Y, Sugaya, T., Kubo, Y, andTsuji, A. L-Type Fatty Acid Binding Protein Transgenic Mouse as a Novel Tool to Explore Cytotoxicity to Renal Proximal Tubules. Drug Metab. Pharmacokinet. 2008;23(4):271-278.
202. Noiri, E., Doi, K., Negishi, K., Tanaka, T., Hamasaki, Y, Fujita, T., Portilla, D., and Sugaya, T. Urinary Fatty Acid-Binding Protein 1:An Early Predictive Bio-marker of Kidney Injury. Am. J. Physiol. Renal Physiol. 2009;296(4):F669-679.
203. Portilla, D., Dent, C, Sugaya, T., Nagothu, K. K., Kundi, I., Moore, P., Noiri, E., and Devarajan, P. Liver Fatty Acid-Binding Protein as a Biomarker of Acute Kidney Injury After Cardiac Surgery. Kidney Int. Feb 2008;73(4):465-72.
204. Yamamoto, T., Noiri, E., Ono, Y, Doi, K., Negishi, K., Kamijo, A., Kimura, K., Fujita, T, Kinukawa, T., Taniguchi, H., Nakamura, K., Goto, M., Shinozaki, N., Ohshima, S., and Sugaya, T. Renal L-Type Fatty Acid-Binding Protein in Acute Ischemic Injury. J. Am. Soc. Nephrol. 2007;18(11):2894-2902.
205. Kamijo, A., Sugaya, T.,Hikawa, A.,Yamanouchi,M., Hirata,Y, Ishimitsu,T., Num-abe,A.,Takagi,M.,Hayakawa,H.,Tabei,F.,Sugimoto,T.,Mise,N.,andKimura, K. ClinicalEvaluationofUrinaryExcretionofLiver-Type Fatty Acid-Binding Protein As a Marker for the Monitoring of Chronic Kidney Disease: A Multicenter Trial. J. Lab. Clin. Med. 2005;145(3):125-133.
206. Nakamura, T., Sugaya, T., Kawagoe, Y, Ueda, Y, Osada, S., and Koide, H. Candesartan Reduces Urinary Fatty Acid-Binding Protein Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease. Am. J. Med. Sci. 2005;330(4):161-165.
207. Nakamura, T., Sugaya, T., Kawagoe, Y, Ueda, Y, Osada, S., and Koide, H. Effect of Pitavastatin on Urinary Liver-Type Fatty Acid-Binding Protein Levels in Patients with Early Diabetic Nephropathy. Diabetes Care. 2005;28(11):2728-2732.
208. Nakamura, T., Sugaya, T., Kawagoe, Y., Ueda, Y., Osada, S., and Koide, H. Urinary Liver-Type Fatty Acid-Binding Protein Levels for Differential Diagnosis of Idiopathic Focal Glomerulosclerosis and Minor Glomerular Abnormalities and Effect of Low-Density Lipoprotein Apheresis. Clin. Nephrol. 2006;65(1):l-6.
209. Hofstra, J. M., Deegens, J. K., Steenbergen, E. J., and Wetzels, J. F. Urinary Excretion of Fatty Acid-Binding Proteins in Idiopathic Membranous Nephropathy. Nephrol. Dial. Transplant. 2008;23(10):3160-3165.
210. Oyama, Y., Takeda, T., Hama, H., Tanuma, A., Iino, N., Sato, K., Kaseda, R., Ma, M., Yamamoto, T., Fujii, H., Kazama, J. J., Odani, S., Terada, Y., Mizuta, K., Gejyo, F, and Saito, A. Evidence for Megalin-Mediated Proximal Tubular Uptake of L-FABP, a Carrier of Potentially Nephrotoxic Molecules. Lab. Invest. 2005;85(4):522-531.
211. Kamijo, A., Sugaya, T, Hikawa, A., Yamanouchi, M., Hirata, Y, Ishimitsu, T, Numabe, A., Takagi, M., Hayakawa, H., Tabei, E, Sugimoto, T, Mise, N., Omata, M., and Kimura, K. Urinary Liver-Type Fatty Acid Binding Protein as a Useful Biomarker in Chronic Kidney Disease. Mol. Cell. Biochem. Mar 2006;284(1-2):175-182.
212. Taupin, D. R., Kinoshita, K., and Podolsky, D. K. Intestinal Trefoil Factor Confers Colonic Epithelial Resistance to Apoptosis. Proc. Natl. Acad. Sci. USA. 2000;97(2):799-804.
213. Kinoshita, K., Taupin, D. R., Itoh, H., and Podolsky, D. K. Distinct Pathways of Cell Migration and Antiapoptotic Response to Epithelial Injury: Structure-Function Analysis of Human Intestinal Trefoil Factor. Mol. Cell. Biol. 2000 (13):4680-4690.
214. Lesimple, P., Van Seuningen, I., Buisine, M. P., Copin, M. C, Hinz, M., Hoffmann, W., Hajj, R., Brody, S. L., Coraux, C, and Puchelle, E. Trefoil Factor Family 3 Peptide Promotes Human Airway Epithelial Ciliated Cell Differentiation. Am. J. Respir. Cell. Mol. Biol. 2007;36(3):296-303.
215. Hoffmann, W. TFF (Trefoil Factor Family) Peptides and Their Potential Roles for Differentiation Processes During Airway Remodeling. Curr. Med. Chem. 2007;14(25):2716-2719.
216. Suemori, S., Lynchdevaney, K., and Podolsky, D. K. Identification and Characterization of Rat Intestinal Trefoil Factor: Tissue- and Cell-Specific Member of the Trefoil Protein Family. Proc. Natl. Acad. Sci. USA. 1991;88(24):11017-11021.
217. Yu, Yan;Jin, Hong;Holder, Daniel;Ozer, Josef S.;Villarreal, Stephanie;Shughrue, Paul;Shi, Shu;Figueroa, David J.;Clouse, Holly;Su, Ming;Mu-niappa, Nagaraja;Troth, Sean P.;Bailey, Wendy;Seng, John;Aslamkhan, Amy G.;Thudium, Douglas;Sistare, Frank D.;and Gerhold, David L. Biomarkers of Kidney Tubule Injury: Urinary Trefoil Factor 3 and Albumin. Submitted (2009).
218. Chinery, R., Poulsom, R., Elia, G., Hanby, A. M., and Wright, N. A. Expression and Purification of a Trefoil Peptide Motif in a Beta-Galactosidase Fusion Protein and Its Use to Search for Trefoil-Binding Sites. Eur. J. Biochem. 1993;212(2):557-563.
219. Baus-Loncar, M., Al-Azzeh, E. D., Romanska, H., Lalani, El-N., Stamp, G. W., Blin, N., and Kayademir, T. Transcriptional Control of TFF3 (Intestinal Trefoil Factor) via Promoter Binding Sites for the Nuclear Factor Kappab and C/Ebp-beta. Peptides. 2004;25(5):849-854.
220. Dossinger, V., Kayademir, T., Blin, N., and Gótt, P. Down-Regulation of TFF Expression in Gastrointestinal Cell Lines by Cytokines and Nuclear Factors. Cell. Physiol. Biochem. 2002;12(4):197-206.
221. Melnikov, V. Y., Ecder, T., Fantuzzi, G., Siegmund, B., Lucia, M. S., Dinarello, C. A., Sender, R. W., and Edelstein, C. L. Impaired IL-18 Processing Protects Caspase-1-Deficient Mice From Ischemic Acute Renal Failure. J. Clin. Invest. 2001;107(9):1145-1152.
222. Lochner, M. and Fórster, I. Anti-Interleukin-18 Therapy in Murine Models of Inflammatory Bowel Disease. Pathobiology. 2002/2003;70(3):164-169.
223. Edelstein, C. L. Biomarkers of Acute Kidney Injury. Adv. Chronic Kidney Dis. 2008;15(3):222-234.
224. Melnikov, V. Y., Faubel, S., Siegmund, B., Lucia, M. S., Ljubanovic, D., and Edelstein, C. L. Neutrophil-Independent Mechanisms of Caspase-1- and IL-18-Mediated Ischemic Acute Tubular Necrosis in Mice. J. Clin. Invest. 2002;110(8):1083-1091.
225. Parikh, C. R., Mishra, J., Thiessen-Philbrook, H., Dursun, B., Ma, Q., Kelly, C, Dent, C, Devarajan, P., and Edelstein, C. L. Urinary IL-18 Is an Early Predictive Biomarker of Acute Kidney Injury After Cardiac Surgery. Kidney Int. 2006;70(1):199-203.
226. Parikh, C. R., Jani, A., Mishra, J., Ma, Q., Kelly, C, Barasch, J., Edelstein, C. L., and Devarajan, P. Urine NGAL and IL-18 are Predictive Biomarkers for Delayed Graft Function Following Kidney Transplantation. Am. J. Transplant. 2006;6(7):1639-1645.
227. Simon, T., Opelz, G., Wiesel, M., Pelzl, S., Ott, R. C, and Süsal, C. Serial Peripheral Blood Interleukin-18 and Perforin Gene Expression Measurements for Prediction of Acute Kidney Graft Rejection. Transplantation. 2004;77(10):1589-1595.
228. Parikh, C. R., Jani, A., Melnikov, V. Y, Faubel, S., and Edelstein, C. L. Urinary Interleukin-18 Is a Marker of Human Acute Tubular Necrosis. Am. J. Kidney Dis. Mar 2004;43(3):405-114.
229. Bulent Gul, C. B., Gullulu, M., Oral, B., Aydinlar, A., Oz, O., Budak, E, Yil-maz, Y, and Yurtkuran, M. Urinary IL-18:A Marker of Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention? Clin. Biochem. 2008;41 (7-8):544-547.
230. Ling, W., Zhaohui, N., Ben, H., Leyi, G., Jianping, L., Huili D, and Jiaqi Q. Urinary IL-18 and NGAL As Early Predictive Biomarkers in Contrast-Induced Nephropathy After Coronary Angiography. Nephron. Clin. Pract. 2008;108(3):C176-181.
231. Haase, M., Bellomo, R., Story, D., Davenport, P., and Haase-Fielitz, A. Urinary Interleukin-18 Does Not Predict Acute Kidney Injury After Adult Cardiac Surgery: A Prospective Observational Cohort Study. Crit. Care. 2008;12(4):R96.
232. Xin, C, Yulong, X., Yu, C, Changchun, C, Feng, Z., and Xinwei, M. Urine Neutrophil Gelatinase-Associated Lipocalin and Interleukin-18 Predict Acute Kidney Injury After Cardiac Surgery. Ren. Fail. 2008;30(9):904-913.
233. Argutusmedical Ltd Homepage, http://www.argutusmed.com.
234. R&D Systems Homepage, www.rndsystems.com.
235. Biovendor Homepage, http://www.biovendor.com.
236. Rules Based Medicine Website, http://www.rulesbasedmedicine.com.
237. Mesoscale Discovery Technology Website, http://www.mesoscale.com/catalog-systemweb/webroot/technology.htm.
238. Devarajan, P. Neutrophil Gelatinase-Associated Lipocalin (NGAL):A New Marker of Kidney Disease. Scand. J. Clin. Lab. Invest. Suppl. 2008;241:89-94.
239. Http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html.
240. EMEA CHMP, Final Conclusions on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers. 2009, http://www.emea.europa.eu/pdfs/human/sciadvice/67971908en.pdf.
241. http://www.fda.govtobs/topics/NEWS/2008/NEW01850.html.
242. HESI 2008 Annual Report, Page 10, http://www.hesiglobal.org/files/public/an-nual%20reports/HESI2008AnnualR eportFinal.pdf.
243. Vaidya, V. S., Waikar, S. S., Ferguson, M. A., Collings, F. B., Sunderland, K., Gioules, C, Bradwin, G., Matsouaka, R., Betensky, R. A., Curhan, G. C., and Bonventre, J. V. Urinary Biomarkers for Sensitive and Specific Detection of Acute Kidney Injury in Humans. Clin. Transí. Sci. 2008;1(3):200-208.
244. Liangos, O., Tighiouart, H., Perianayagam, M. C, Kolyada, A., Han, W. K., Wald, R., Bonventre, J. V., and Jaber, B. L. Comparative Analysis of Urinary Biomarkers for Early Detection of Acute Kidney Injury Following Cardiopulmonary Bypass. Biomarkers. 2009 In Press.